Sandoz announced the creation of a standalone biosimilars business unit and named Armin Metzger to lead development, manufacturing and supply as the company targets an expected decade of biologic patent expiries. Management said the split will enable faster decisions and clearer accountability between biosimilars and small‑molecule generics. The move follows industry shifts and recent regulatory steps aimed at streamlining biosimilar entry. In parallel, the U.S. FDA updated draft guidance easing some clinical pharmacokinetic comparators, reducing burdens for biosimilar sponsors. Taken together, corporate reorganization and regulatory easing could accelerate biosimilar launches and pricing competition in biologics markets.